The European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that Prostate-Specific Antigen (PSA) based screening results in a significant prostate cancer mortality reduction. Although there are concerns on overdiagnosis and overtreatment, it has been shown that the benefits can outweigh the harms if screening is stopped in older ages to prevent overdiagnosis. A limited screening program (for example screening at ages 55-59 years), including active surveillance for men with low-risk tumors, can even be cost-saving, compared with testing in an opportunistic setting in the wrong ages, as currently in Europe. Further improvements are expected in the use of active surveillance and in discrimination between indolent and significant disease due to new biomarkers and magnetic resonance imaging. However, these future developments are no reason to postpone feasibility studies of high-quality PSA screening and reduce opportunistic testing at old ages.
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Worldwide, >1 million men each year receive the diagnosis prostate cancer and >300,000 die from the disease. 1 Screening for prostate cancer has been debated for many years, especially after the concurrent publication of two trials with seemingly contradicting results. This article is a summary of the European consensus meeting involving >30 experts from Europe. The evidence on benefits, harms and cost-effectiveness of prostate cancer screening will be discussed, based on trials, literature and model calculations. An example for a limited screening programme will be given. None of international literature or policy makers so far considered such a programme. Also, current developments that in the future can improve a prostate cancer screening programme, gaps in knowledge, and further steps are described.
Benefits of PSA Screening: Prostate Cancer Mortality Reduction Results of Randomized Controlled Trials
Until now, five prostate cancer screening trials have published their results, of which three trials were small and classified as having a high risk of bias. 2 The European Randomised Study of Screening for Prostate Cancer (ERSPC) randomized 162,243 men from seven European countries in the core age group of 55-69 years to an intervention or control arm. 3 The main screening protocol consisted of PSA test every 4 years. A PSA result of 3.0 ng/ml or higher was followed by a biopsy. After 13 years of follow-up, the relative risk reduction of prostate cancer mortality was 21% in favor of screening (RR 5 0.79, 95% CI 0.69-0.91), and 27% when adjusting for non-participation. 3 The absolute prostate cancer mortality reduction was 1.28 per 1,000 men randomized. The US Prostate, Lung, Colorectal and Ovarian (PLCO) trial was conducted in 76,693 men aged 55-74 among whom prior screening was already common. 4 Annual screening was used and the threshold for a positive PSA test was 4.0 ng/ml or a positive digital rectal exam. The trial showed no benefit of screening on prostate cancer mortality (RR 5 1.04, 95% CI 0.87-1.24), but the low biopsy compliance (35%) 5 and high degree of contamination complicates the interpretation of the results. Three simulation models found that pre-trial and control arm screening substantially reduced the power of the PLCO to detect a prostate cancer mortality difference between arms to <25%.
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Given the high risk of bias in most trials and the high degree of contamination in the PLCO, meta-analyses combining these trials with the ERSPC, as done in the Cochrane reviews 2, 7 should be interpreted with caution. One trial is still ongoing: The CAP/ProtecT trial in the UK, 8 randomizing 415,000 men. However, since the attendance is only 45% and a single PSA test is done, the results will possibly be of limited additional value in this screening aspect.
Harms of prostate cancer screening
Screening can also cause harm in each phase of the process: screening, diagnosis, treatment and post-treatment. The positive predictive value of a biopsy (using 3 ng/ml as cut-off for referral to biopsy) is 20-25%, therefore >75% of positive PSA tests are followed by a negative biopsy. Biopsies can cause infections in 0.7-4.2%, 9,10 although a minority required hospitalization. 11 Both the PLCO and the ERSPC reported no biopsy related deaths. 9, 12 Receiving a diagnosis of prostate cancer leads to a significant drop in quality of life, persisting for at least several months. 13 Since the lead-time is long (estimated to about 5-12 years), 14, 15 men have to live longer with the knowledge of having cancer. Most important harms in prostate cancer screening are overdiagnosis and overtreatment. Overdiagnosed cancers are cancers that would not have been detected in the absence of screening. These people will be treated and possibly live with the complications of treatment, whereas without screening they would not have been diagnosed with cancer at all. Published estimates of overdiagnosis range from 27 to 56% of all screen detected cancers (depending on the screening protocol). 14, 15 Side-effects of prostate cancer treatment are problems in urinary, bowel and sexual functioning, which can persist for several years after the treatment [16] [17] [18] [19] [20] and involve up to 60% of the men treated with radical prostatectomy or radiation therapy. However, there are hardly any studies with >5 years of follow-up after treatment. 19 Recently, the ProtecT trial published 6 year follow-up patient reported outcomes comparing radical prostatectomy, radiation therapy and active surveillance. Prostatectomy had the greatest negative effect on sexual function and urinary continence, especially in the first 6 months. 21 
Weighing benefits and harms
There is enough evidence in the literature to reasonably estimate the number of prostate cancer deaths prevented, the number of biopsies, overdiagnosis, treatments and complications for several screening protocols. However, the decision about where the balance lies is subjective. The trade-off between harms and benefits can be determined by using quality-adjusted life years (QALYs) based on utility estimates.
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Using modeling based on ERSPC data, life span predictions estimated were made. 23 In this MISCAN model, individual life histories were simulated in which the natural history of prostate cancer was modeled. For exactly the same population, the model predicted the life histories in the absence and in the presence of a screening programme. The results showed that annual screening of men between the ages of 55 and 69 years would result in nine fewer deaths from prostate cancer (28% reduction), and a total of 73 lifeyears gained (on average 8.4 years per prostate cancer death avoided) per 1,000 men. 23 The number of QALYs that were gained was 56 in this annual protocol.
Advantageous Protocol
Based on cost-effectiveness (see below), a more limited programme, screening at ages 55, 57 and 59, was also quantified. For this strategy, a 13% lifetime prostate cancer mortality reduction (4 per 1,000 men invited) was predicted. The favorable and unfavorable effects of screening at ages 55, 57 and 59 are presented in Figure 1 . Per 1,000 men, 7 gained QALYs because palliative therapy for prostate cancer is prevented and 16 men had a small loss in quality of life because of treatment. In this screening protocol, 32% of the men with screen detected cancer will be overdiagnosed. 24 Cost-effectiveness of prostate cancer screening Using the MISCAN model based on the ERSPC trial, the cost-effectiveness of 68 PSA screening strategies was evaluated. 24 The screening strategies started at age 55 years and varied by age to stop screening and screening interval. Screening at short intervals of 3 years or less was more costeffective than using longer intervals. Screening at ages 55, 57 and 59 had an incremental cost-effectiveness ratio of e44,000 ($73,000) per QALY gained (3.5% discount for costs and effects) and was considered optimal for a threshold of e50,000 per QALY gained (Table 1) . Screening above age 63 years was less cost-effective because of loss of QALYs due to overdiagnosis. Our estimates did not take opportunistic testing into account. Three other studies have used the ERSPC results to assess cost-effectiveness of screening. [25] [26] [27] One study, based on the ERSPC 9 year follow-up results, using a screening protocol of on average 2.1 screens between age 60 and 70, found a costeffectiveness of $262,758 per life year gained. 27 They did not adjust for quality of life. Another study assessed the costeffectiveness of screening in British Columbia. 26 They evaluated a variety of screening protocols, including a single screen at different ages. The cost-effectiveness of screening at ages 55-69 with 4 year intervals was $36,300, however when taking QALYs into account, the incremental cost-effectiveness was more than $300,000 per QALY for all strategies. The third study found a cost-effectiveness of $291,817 per QALY for a 4 year screening strategy, however, the age range of screening is not clear. 25 The results of these three studies are difficult to compare because of different assumptions in demographics and background risks, screening protocols, costs, effects of treatment and screening on mortality, utilities, and discount rates.
But most crucial, none of these studies evaluated screening programmes limited to age range 55-59.The MISCAN model also found that screening is not cost-effective if screening is extended to older ages.
Current status of prostate cancer screening
In the US, the US Preventive Services Task Force (USPSTF) has recently changed the previous D-recommendation (against prostate cancer screening) to a draft C-recommendation, urging clinicians to inform men between age 55 and 69 about the potential benefits and harms of prostate cancer screening. The Figure 1 . Favorable and unfavorable effects of prostate cancer screening at ages 55, 57 and 59 per 1,000 men with life time follow-up. The numbers are compared with 1,000 men in a situation without screening. The scale represents relative weights given to different phases in the process of screening, diagnosis and treatment. Therefore, compared with a no screening situation, seven men less will receive palliative therapy for 30 months each and with a quality of life of 60% of maximum. Note: active surveillance is about 30%, based on ERSPC data. 1 The incremental cost-effectiveness is calculated by comparing the additional effects and costs for a strategy with the previous strategy.
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American Urological Association (AUA) recommends shared decision making for men age 55-69 that are considering PSA screening. 28 To date, Lithuania is the only country with a nation-wide screening programme. 29 However, in many countries there is widespread opportunistic screening since >10-20 years, especially at older ages. 30, 31 For example in Stockholm, 25% of the men aged 50-59 had a PSA test, increasing to 46% at age 70-79 in the period 2010-2011. 31 Since at older ages the probability of overdiagnosis is extremely high, the harms of this opportunistic screening will outweigh the benefits.
Benefits of an organized programme in comparison with opportunistic screening
For several combinations of a screening programme and opportunistic screening, the costs and QALYs gained have been predicted, using the MISCAN model (Table 2) . When 25% of the men attend screening at ages 55, 57 and 59 and continue biennial opportunistic screening at a rate of 40% between age 60-69 and 46% at age 70-79, the total costs of prostate cancer screening, diagnosis and treatment per 1,000 men followed over life-time will be 1.67 million euro more than in a situation without any screening, and 0.9 QALYs will be gained. Introducing a screening programme should be accompanied by a decrease in opportunistic screening. When 80% of men attend screening and only half of the men continue opportunistic screening, the net costs are 1.55 million euro and 6.7 QALYs will be gained. Therefore, a populationbased screening programme can lead to a better balance between harms and benefits and can even be cost-saving, compared with screening in an opportunistic setting in the wrong, older, ages, even when some men continue testing after the stop age of the programme.
Current Developments

Active surveillance
The aim of active surveillance is to delay or avoid treatment, and therefore suffering from the consequences of treatment. Patients in active surveillance are offered PSA tests, prostate biopsies and more recently mpMRI. When the disease progresses, active treatment will follow. Several active surveillance studies have been initiated worldwide. 32 So far the results are promising. Even in the ProtecT trial, in which also men with Gleason score 7 or higher were randomized to active surveillance, the 10-year prostate cancer specific survival was 98.8%. 33 However, it must be noted that 54.8% of men assigned to active surveillance received radical treatment during the 10 years of follow-up. 33 Although there is perhaps not a worldwide consensus on the inclusion criteria, surveillance schedules and intervention thresholds, 34 the number of men on active surveillance is increasing strongly.
35,36
Biomarkers and risk prediction models
The PSA test has a high false-positive rate that translates into unnecessary prostate biopsies. Also, the test detects low-grade prostate cancers, leading to overdiagnosis. After a positive PSA test, biomarkers, such as the Beckman Coulter Prostate Health Index (PHI) and the OPKO 4K score can be used as a referral test to decide whether a biopsy is necessary. Using these biomarkers 15 to 65% of the biopsies could be avoided, to the cost of delaying the diagnosis for about 5-10% of the men with a significant cancer (Gleason score 7). [37] [38] [39] A combination of biomarkers, genetics and clinical variables was tested in the Stockholm 3 (STHLM3) study. 40 Use of the STHLM3 model could reduce the number of biopsies by 32% and Gleason 6 cancers by 17%.
There are also risk calculators available, which can predict the risk of prostate cancer within the next couple of years based on, for example, age, PSA, DRE, family history, prostate volume, and having had a previous negative biopsy. These tools can reduce the number of future PSA tests, biopsies or overdiagnosis. 41 
mpMRI
The limitations of a TRUS guided biopsy are a relatively poor detection of significant prostate cancer (Gleason score 7 or more), inaccurate prognostic stratification in men diagnosed with cancer, and the overdetection of insignificant prostate cancer. Multiparametric magnetic resonance imaging (mpMRI) provides better anatomic and functional imaging of the prostate than other imaging methods. 42 It is found that pre-biopsy mpMRI improved the detection of clinically significant prostate cancer, while avoiding 20-30% unnecessary Table 2 . Total net costs (in million euro) and QALYs gained (without discount) per 1,000 men followed over life time for three different screening scenarios, consisting of a screening programme for age 55-59 in combination with opportunistic screening at the higher ages All scenarios are compared with a no screening scenario. 1 Based on the proportion of men having received a PSA test in 2010-2011. 31 2 Half of the men continue screening after the screening programme.
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biopsies. 43 Therefore, mpMRI could be a powerful diagnostic tool for the detection of clinically significant prostate cancer and reduce unnecessary biopsies after a positive PSA test.
Risk-based strategies and genomics
Another way to improve the harms-benefits trade-off of the effects of screening is to tailor screening to the risk of prostate cancer.
Men with a PSA <1.0 at age 45 or age 60 have a low probability to be diagnosed with prostate cancer later in life and almost no risk on prostate cancer death. [44] [45] [46] Therefore, screening less in men with low baseline PSA can considerably reduce the number of future screenings. Increasing the PSA threshold for men at older ages can substantially reduce the harms (about 30% less overdiagnosis). 47, 48 Also genomics can be used to stratify screening. Men in the top 10% of the risk distribution have a 2.9-fold increased risk of prostate cancer compared with the average population. 49 An earlier analysis demonstrated that screening stratified by polygenic risk can substantially reduce the number of men eligible for screening while potentially detecting almost the same amount of cancers. 50 
Results of the Consensus Meeting
The participants of the consensus meeting strongly agreed that PSA screening can substantially reduce prostate cancer mortality and that an organized programme will lead to a better situation than opportunistic testing, provided that there is a system in place for quality assurance and that there is appropriate referral to active surveillance. There was more disagreement on the possible impact of evidence from future trials or studies. According to the participants, the most important gaps in knowledge are the amount of uncontrolled PSA testing when a programme is in place (will men stop at the end age of the programme), future utilization of active surveillance, combining MRI, biomarkers and risk calculators, and long term effects of treatment.
Remaining questions
The ERSPC trial has proven that prostate cancer screening is effective in reducing the numbers of prostate cancer deaths. Recently, the harms and benefits have been quantified and the cost-effectiveness has been evaluated. The next step in the process to decide on the appropriateness of screening is to perform feasibility studies. Five questions remain especially important for prostate cancer screening:
1. What is the information to be given to participants, to be able to reach informed-decision making? 2. Do existing screening organization systems deliver highest quality assurance, higher than through individual GPs? 3. What is the attendance rate? 4. What is the extent of active surveillance in screen detected men? 5. Is it realistic that men discontinue opportunistic screening at older age after having participated in a population-based screening programme?
These questions should be evaluated in pilot studies with a limited number of participants.
Conclusion
Currently, the evidence for effectiveness, balance between harms and benefits and cost-effectiveness of prostate cancer screening justifies starting pilot studies for the implementation of limited prostate cancer screening. Future developments in biomarkers, risk predictors, MRI, active surveillance and stratified screening strategies can further improve the harm-benefit trade-offs and therefore the cost-effectiveness. A well organised programme in a relative small age range is preferred above the currently considerable amount of opportunistic testing at older ages.
